Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Jesse Mendelsohn
Predicting 2025 Trends: Jesse Mendelsohn from Model N in an Illuminating Discussion with PharmaShots
Shots:  Several undulating factors coalesce to inadvertently shape the biopharma industry  Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list.  Jesse Mendelsohn, SVP at Model N, emphasizes the…
April 28, 2025
Viewpoints_Vijay Nadipelli
Evaluating SDoH in SLE: Vijay Nadipelli from GSK in a Riveting Conversation with PharmaShots
Shots:  SDoH screening can help identify patient needs, support faster clinical decisions, and improve patient-centric care  A first-of-its-kind lupus study surveyed 69 patients across two institutions to assess the feasibility of routine SDoH screening in lupus clinics and identify related barriers and enablers at the physician, care team, and patient levels  Vijay Nadipelli, Senior Director…
April 21, 2025
Viewpoints_Anton Yarovoy
Driving Precision Medicine Education: A Star Wars-Themed Talk on a Needed Approach
Shots:    Precision Medicine is a rapidly evolving field offering targeted treatments for optimal patient care    Education around testing is a critical need as many barriers exist that create practice gaps to patient identification   Testing State Awareness (TSA) is a critical component that needs to complement Brand and Disease State Awareness campaigns    Anton Yarovoy, Group Product…
April 18, 2025
Viewpoints_Kate Flathers
Streamlining Pharmaceutical Claims: Kate Flathers from Kalderos in a Stimulating Conversation with PharmaShots
Shots:   Streamlining claims transactions remains a major challenge for pharmaceutical manufacturers. The financial leakage owing to non-compliant and duplicate claims costs manufacturers a fortune   Using Kalderos' Truzo platform, manufacturers can pay covered entities directly while maintaining transparency and compliance  Kate Flathers, Chief Product Officer at Kalderos, addresses the need for a compliant model for claims…
April 17, 2025
Viewpoints_Raphaël Ortiz
Enhancing Diagnostic Capabilities in Prostate Cancer: Raphaël Ortiz from Telix Pharmaceuticals in a Riveting Conversation with PharmaShots
Shots:  Telix Pharmaceuticals’ Illuccix is approved in the UK for detecting and localizing prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET imaging.  Amidst a shortage of PET imaging agents in the UK and mainland Europe, Telix Pharmaceuticals has secured a significant advantage through an exclusive distribution partnership with Xiel Limited  Raphaël…
April 7, 2025
Viewpoints_Roger Levy
Evaluating SDoH in Lupus Nephritis: Roger Levy from GSK in a Stimulating Conversation with PharmaShots
Shots:  GSK presented data at the American College of Rheumatology from a multi-center cohort study highlighting the achievement of complete renal response in patients with active lupus nephritis  The study evaluated the attainment of modified complete renal response (mCRR) in patients with systemic lupus erythematosus (SLE) and active lupus nephritis (LN), comparing characteristics between mCRR…
April 2, 2025
Viewpoints_Anabela Cardoso_Mark Genovese
Lilly at ACG 2024: Anabela Cardoso and Mark Genovese in Conversation with PharmaShots
Shots:  Lilly presented results from two long-term studies evaluating sustained efficacy in patients treated with mirikizumab for both moderately to severely active Ulcerative Colitis and Crohn’s Disease at ACG 2024  At three years, more than 80 percent of patients with moderately to severely active ulcerative colitis who were on remission sustained long-term remission and relief  …
March 24, 2025
Viewpoints_Uwe Gudat
Biocon Biologics at AAO 2024: Uwe Gudat in an Invigorating Discussion with PharmaShots
Shots: At the American Academy of Ophthalmology (AAO 2024), Biocon Biologics announced promising results from the extension study of its proposed biosimilar to aflibercept, MYL-1701P The study demonstrated comparable safety, efficacy, and immunogenicity between patients continuing MYL-1701P and those who switched from aflibercept to MYL-1701P Biocon Biologics' Chief Medical Officer, Uwe Gudat, discusses the groundbreaking…
March 17, 2025
Viewpoints_Caterina Brindicci
Enhancing Autoimmune Care: Caterina Brindicci from AstraZeneca in a Riveting Conversation with PharmaShots
Shots:   SLE-related diseases like CLE and IIM are characterized by strong type I interferon involvement. The proven efficacy of Saphnelo (anifrolumab) in SLE lays the foundation for its potential use in CLE and IIM  Recently, AstraZeneca initiated two new P-III trials, LAVENDER and JASMINE, to evaluate Saphnelo in cutaneous lupus erythematosus and idiopathic inflammatory myopathies …
March 3, 2025
Viewpoints_Mina Makar
A Retrospective Analysis on Cardiac Amyloidosis: Mina Makar from AstraZeneca in an Illuminating Conversation with PharmaShots
Shots:  A UK observational study spanning 17 years shows a 2.9-fold increase in Cardiac Amyloidosis diagnoses, highlighting significant progress in awareness among healthcare professionals and advancements in diagnostic tools  The study underscores the importance of improving the identification and treatment of Cardiac Amyloidosis, particularly in cases with overlapping conditions such as heart failure  Mina Makar,…
February 24, 2025
Load more